MA3-L

MA3-L is an mRNA-based cancer vaccine encapsulated in lipid nanoparticles (LNPs) designed to target the α3 domain of MICA and MICB (MICA/B). Developed by ProMab Biotechnologies, the vaccine encodes the membrane-proximal α3 domain of these stress-induced ligands. Upon administration, it elicits a humoral immune response, producing antibodies that bind to the α3 domain on the surface of tumor cells. This binding sterically hinders the proteolytic cleavage and subsequent shedding of the MICA/B α1/2 domains, a common mechanism by which tumors evade immune detection. By maintaining MICA/B on the cell surface, the vaccine prevents the downregulation of the NKG2D receptor on NK cells and T cells, thereby enhancing the immune system's ability to recognize and eliminate metastatic cancer cells. Preclinical studies have demonstrated its efficacy in models of colorectal cancer, melanoma, and breast cancer.

Other names

mRNA-MICA-alpha3-LNPmRNA-MICA-alpha-3-LNPmRNA-MICA-alpha 3-LNPmRNA-alpha3-LNPmRNA-alpha-3-LNPmRNA-alpha 3-LNP